Neoplasm Metastasis  >>  Tekturna (aliskiren)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tekturna (aliskiren) / PDL
NCT01150357 / 2009-017028-22: Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Completed
3
267
US, Europe, RoW
Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
Novartis Pharmaceuticals
Hypertension
08/14
08/14
NCT01151410 / 2009-017029-20: An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age

Completed
3
208
US, Europe, RoW
Aliskiren, Enalapril
Novartis Pharmaceuticals
Hypertension
08/15
08/15

Download Options